CORCEPT THERAPEUTICS INC
Business
Corcept Therapeutics is a commercial-stage pharmaceutical company that discovers and develops selective cortisol-modulating medications for endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym (mifepristone) and an authorized generic version in the United States for hypercortisolism treatment, and is advancing proprietary cortisol modulators including relacorilant, nenocorilant, miricorilant and dazucorilant through clinical trials for hypercortisolism, solid tumors (ovarian, endometrial, cervical, pancreatic and prostate cancers), metabolic dysfunction-associated steatohepatitis, and amyotrophic lateral sclerosis. The company distributes products through specialty pharmacies and medical science liaisons to physicians treating patients with these disorders.
Summary from 10-K filed 2026-02-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product revenue, net | 761 | 675 | 482 | 402 | 366 | |
| Cost of sales | 13 | 11 | 6 | 5 | 5 | |
| Research and development | 255 | 247 | 184 | 131 | 114 | |
| Selling, general and administrative | 449 | 280 | 184 | 153 | 122 | |
| Total operating expenses | 717 | 538 | 375 | 289 | 242 | |
| Income from operations | 45 | 137 | 107 | 113 | 124 | |
| Interest and other income | 22 | 25 | 17 | 4 | 529,000 | |
| Income before income taxes | 66 | 161 | 125 | 116 | 125 | |
| Income tax benefit (expense) | 33 | −20 | −18 | −15 | −12 | |
| Net income | 100 | 141 | 106 | 101 | 113 | |
| Net income attributable to common stockholders, basic | 98 | 140 | 105 | 101 | 113 | |
| Net income attributable to common stockholders, diluted | 98 | 140 | 105 | 101 | 113 | |
| Basic net income per share (in dollars per share) | 0.95 | 1.35 | 1.02 | 0.95 | 0.97 | |
| Diluted net income per share (in dollars per share) | 0.82 | 1.23 | 0.94 | 0.87 | 0.89 | |
| Basic (in shares) | 104 | 103 | 104 | 107 | 116 | |
| Diluted (in shares) | 120 | 113 | 112 | 116 | 126 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 120 | 128 | 136 | 66 | 78 | |
| Short-term marketable securities | 252 | 256 | 233 | 365 | — | |
| Trade receivables, net of allowances | 60 | 54 | 41 | 31 | 28 | |
| Inventory | 13 | 12 | 8 | 6 | 5 | |
| Prepaid expenses and other current assets | 41 | 22 | 28 | 16 | 10 | |
| Total current assets | 485 | 472 | 459 | 499 | 266 | |
| Strategic inventory | 11 | 4 | 8 | 11 | 13 | |
| Operating lease right-of-use asset | 5 | 5 | 120,000 | 1 | 514,000 | |
| Property and equipment, net | 2 | 3 | 195,000 | 633,000 | 1 | |
| Long-term marketable securities | 160 | 220 | 57 | 5 | — | |
| Other assets | 5 | 7 | 7 | 5 | 3 | |
| Deferred tax assets, net | 168 | 131 | 91 | 61 | 27 | |
| Total assets | 837 | 841 | 622 | 583 | 424 | |
| Accounts payable | 40 | 15 | 17 | 12 | 7 | |
| Accrued research and development expenses | 34 | 34 | 21 | 15 | — | |
| Accrued and other liabilities | 91 | 91 | 52 | 31 | 28 | |
| Short-term operating lease liability | 1 | 829,000 | 151,000 | 1 | 526,000 | |
| Total current liabilities | 166 | 141 | 105 | 72 | 48 | |
| Long-term operating lease liability | 5 | 6 | 0 | — | 0 | |
| Long-term accrued government rebates | 3 | 0 | — | — | — | |
| Long-term accrued income taxes payable | 15 | 14 | 10 | 9 | 409,000 | |
| Total liabilities | 189 | 161 | 115 | 82 | 48 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | — | 0 | 0 | |
| Common stock, par value $0.001 per share, 280,000 shares authorized and 142,518 issued and 105,966 outstanding as of December 31, 2025 and 137,753 shares issued and 105,113 outstanding as of December 31, 2024 | 140,000 | 136,000 | — | 131,000 | 127,000 | |
| Treasury stock; at cost; 36,552 shares of common stock as of December 31, 2025 and 32,640 shares of common stock as of December 31, 2024 | −967 | −696 | −635 | −456 | −410 | |
| Additional paid-in capital | 969 | 832 | — | — | — | |
| Accumulated other comprehensive income (loss) | 2 | −217,000 | 609,000 | −869,000 | −227,000 | |
| Retained earnings | 643 | 544 | 403 | 296 | 195 | |
| Total stockholders equity | 648 | 680 | 507 | 502 | 376 | |
| Total liabilities and stockholders equity | 837 | 841 | 622 | 583 | 424 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 85 | 61 | 49 | 42 | 43 | |
| Accretion of discount on marketable securities, net | −5 | −11 | −9 | 1 | 5 | |
| Depreciation and amortization | 1 | 795,000 | 1 | 1 | 1 | |
| Deferred income taxes | −38 | −40 | −29 | −34 | 4 | |
| Amortization of right-of-use asset | 741,000 | 541,000 | 1 | 2 | 2 | |
| Trade receivables | −6 | −13 | −10 | −3 | −1 | |
| Insurance recovery receivable related to Melucci litigation (Note 10) | 0 | 14 | 0 | — | — | |
| Inventory | −7 | 305,000 | 1 | 1 | 3 | |
| Prepaid expenses and other current assets | −19 | 5 | −12 | −7 | −4 | |
| Other assets | 1 | −69,000 | −1 | −2 | 2 | |
| Accounts payable | 25 | −2 | 5 | 5 | −4 | |
| Accrued research and development expenses | 86,000 | 13 | 7 | 2 | −1 | |
| Accrued and other liabilities | 4 | 38 | 18 | 3 | 6 | |
| Accrued settlement related to Melucci litigation (Note 10) | 0 | −14 | 0 | 14 | 0 | |
| Long-term accrued income taxes | 1 | 4 | 1 | 9 | 11,000 | |
| Operating lease liability | −829,000 | 183,000 | −1 | −2 | −2 | |
| Net cash provided by operating activities | 142 | 198 | 127 | 120 | 168 | |
| Purchases of property and equipment | −211,000 | −2 | −139,000 | −413,000 | −469,000 | |
| Proceeds from maturities of marketable securities | 390 | 413 | 420 | 241 | — | |
| Purchases of marketable securities | −320 | −588 | −329 | −355 | −313 | |
| Net cash provided (used in) by investing activities | 70 | −178 | 91 | −114 | 136 | |
| Proceeds from stock option exercises, net of issuance costs | 16 | 4 | 2 | — | — | |
| Proceeds from purchases under the Employee Stock Purchase Program | 10 | 5 | 4 | 990,000 | — | |
| Repurchases of common stock in connection with Stock Repurchase Program | −173 | −16 | 0 | 0 | — | |
| Repurchase of common stock in connection with Tender Offer | 0 | 0 | −145 | 0 | — | |
| Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants | −73 | −22 | −9 | −22 | −23 | |
| Net cash used in financing activities | −220 | −28 | −149 | −17 | −303 | |
| Net effect of exchange rate changes on cash and cash equivalents | 1 | −228,000 | 358,000 | — | — | |
| Net (decrease) increase in cash and cash equivalents | −7 | −8 | 69 | −11 | 1 | |
| Income taxes paid | 13 | 60 | 48 | 40 | 9 | |
| Exercise cost of shares repurchased for net settlement of cashless option exercises | 25 | 21 | 25 | 24 | 16 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CORCEPT THERAPEUTICS INC's CIK number?
CORCEPT THERAPEUTICS INC's SEC CIK number is 0001088856 (1088856). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CORCEPT THERAPEUTICS INC's SEC filings?
All of CORCEPT THERAPEUTICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CORCEPT THERAPEUTICS INC last report earnings?
CORCEPT THERAPEUTICS INC (CORT) most recently filed an earnings 8-K with the SEC on Apr 30, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-028892). This is CORCEPT THERAPEUTICS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is CORCEPT THERAPEUTICS INC's most recent earnings 8-K?
CORCEPT THERAPEUTICS INC's latest earnings 8-K (Item 2.02) was filed Apr 30, 2026 under accession 0001628280-26-028892. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CORCEPT THERAPEUTICS INC's latest earnings 8-K →
Look up any company's CIK number →